Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Comparing Medications for Adults With Type 2 Diabetes

Slide: 26 of 35

Hypoglycemic Adverse Events: Comparisons of Monotherapies

Mild to Moderate Hypoglycemia
There was high strength of evidence to conclude that the risk of hypoglycemia with sulfonylureas exceeds the risk with metformin with a  pooled OR for mild to moderate hypoglycemic events of 4.6 (95 percent CI, 3.2 to 6.5) for sulfonylurea versus metformin. There was high strength of evidence to conclude that the risk of hypoglycemia with sulfonylureas exceeds the risk with thiazolidinediones with a pooled OR of 3.9, 95 percent CI, 3.0 to 4.9 for mild to moderate hypoglycemia. Moderate-grade evidence showed that the risk of hypoglycemia with sulfonylurea exceeds the risk with DPP-4 inhibitors. Moderate-grade evidence showed a modest increase (OR 3.0, 95 percent, CI 1.8 to 5.2) in risk of hypoglycemia with meglitinides over metformin. Moderate-grade evidence also showed that the risk of hypoglycemia with metformin is comparable to the risk with thiazolidinediones.